EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathwaynews2026-03-03T16:33:03+00:00March 3rd, 2026|Endpoints News|
Corrected: Hims’ pharmacy partner won’t reintroduce GLP-1 pill pulled from marketnews2026-03-03T14:24:24+00:00March 3rd, 2026|Endpoints News|
ICER to CMS: Lower Takeda blockbuster’s price to Stelara’s levelnews2026-03-03T14:03:50+00:00March 3rd, 2026|Endpoints News|
Esperion to buy Corstasis and its nasal spray for edema for $75M upfrontnews2026-03-03T11:56:39+00:00March 3rd, 2026|Endpoints News|
Two more members added to ACIP ahead of March meetingnews2026-03-02T20:35:20+00:00March 2nd, 2026|Endpoints News|
United Therapeutics to take pulmonary hypertension drug to FDA for approvalnews2026-03-02T16:24:51+00:00March 2nd, 2026|Endpoints News|
Roche gets third pivotal win with MS drug, but liver signal could be a problemnews2026-03-02T15:25:33+00:00March 2nd, 2026|Endpoints News|
Bavarian Nordic CEO Paul Chaplin exits, months after failed $3B takeovernews2026-03-02T14:09:32+00:00March 2nd, 2026|Endpoints News|
Novartis’ Rhapsido shows promise in Phase 2 food allergy datanews2026-02-28T19:45:09+00:00February 28th, 2026|Endpoints News|
Ascendis wins FDA approval for achondroplasia drug, waits on EU actionnews2026-02-27T22:52:42+00:00February 27th, 2026|Endpoints News|
